## **Core Concept**
The management of rheumatoid arthritis (RA) often involves a stepwise approach, starting with disease-modifying antirheumatic drugs (DMARDs) like methotrexate, alongside steroids and NSAIDs for symptomatic relief. When there is an inadequate response to initial therapy, the next steps involve either optimizing the current DMARD regimen, adding another DMARD, or switching to a biologic agent.

## **Why the Correct Answer is Right**
The correct approach in a patient who has had no retardation of disease progression on methotrexate, steroids, and NSAIDs would be to consider adding or switching to another DMARD or a biologic agent. Among the given options (though not explicitly listed), a common next step would be to consider adding a biologic DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARD), or switching to a different conventional synthetic DMARD (csDMARD). However, without specific options provided, a general principle is that if a patient fails to respond to methotrexate, one could consider adding another csDMARD (like sulfasalazine, hydroxychloroquine) in combination (a strategy known as "combination DMARD therapy") or introducing a biologic agent.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not provided, but generally, if it suggests stopping current therapy without a replacement, it would be incorrect because discontinuing effective (or partially effective) therapy without a suitable alternative could lead to disease flare.
- **Option B:** Similarly, without specifics, if this option suggests an inappropriate next step (e.g., adding a therapy that is not indicated or is duplicative without rationale), it would be incorrect.
- **Option C:** If this option suggests an inappropriate or less optimal next step compared to others (e.g., merely increasing NSAIDs or steroids without addressing the DMARD regimen), it would be incorrect because it does not adequately address the lack of response to DMARD therapy.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is the "window of opportunity" in RA treatment, which suggests that early aggressive treatment can improve long-term outcomes. When a patient is not responding to initial DMARD therapy, prompt consideration of combination DMARD therapy or the addition of a biologic agent is crucial. The concept of "treat-to-target" guides the management, aiming for remission or low disease activity.

## **Correct Answer: B.**